Fig. 2.
Overall survival of AML patients with a complex karyotype defined as 3 or more, 3 or 4, and 5 or more abnormalities (abn; excluding patients with t(8;21), inv(16)/t(16;16), and t(9;11)) and of patients with a normal karyotype for comparison.
Overall survival of AML patients with a complex karyotype defined as 3 or more, 3 or 4, and 5 or more abnormalities (abn; excluding patients with t(8;21), inv(16)/t(16;16), and t(9;11)) and of patients with a normal karyotype for comparison.
